IGM Biosciences Inc. (IGMS)
IGM Biosciences Statistics
Share Statistics
IGM Biosciences has 59.78M shares outstanding. The number of shares has increased by 1.15% in one year.
| Shares Outstanding | 59.78M |
| Shares Change (YoY) | 1.15% |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | 35.74% |
| Shares Floating | 28.43M |
| Failed to Deliver (FTD) Shares | 1.37K |
| FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 1.96M, so 3.29% of the outstanding shares have been sold short.
| Short Interest | 1.96M |
| Short % of Shares Out | 3.29% |
| Short % of Float | 6.38% |
| Short Ratio (days to cover) | 2.59 |
Valuation Ratios
The PE ratio is -1.89 and the forward PE ratio is -1.03. IGM Biosciences's PEG ratio is 0.06.
| PE Ratio | -1.89 |
| Forward PE | -1.03 |
| PS Ratio | 138.02 |
| Forward PS | 2.8 |
| PB Ratio | 7.68 |
| P/FCF Ratio | -2.33 |
| PEG Ratio | 0.06 |
Enterprise Valuation
IGM Biosciences Inc. has an Enterprise Value (EV) of 362.11M.
| EV / Earnings | -1.85 |
| EV / Sales | 135.16 |
| EV / EBITDA | -1.74 |
| EV / EBIT | -1.74 |
| EV / FCF | -2.28 |
Financial Position
The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.94.
| Current Ratio | 5.14 |
| Quick Ratio | 5.14 |
| Debt / Equity | 0.94 |
| Total Debt / Capitalization | 48.4 |
| Cash Flow / Debt | -3.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -4.06% and return on capital (ROIC) is -223.42%.
| Return on Equity (ROE) | -4.06% |
| Return on Assets (ROA) | -0.74% |
| Return on Capital (ROIC) | -223.42% |
| Revenue Per Employee | $17,979.87 |
| Profits Per Employee | $-1,314,060.4 |
| Employee Count | 149 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.74% in the last 52 weeks. The beta is 0.36, so IGM Biosciences's price volatility has been higher than the market average.
| Beta | 0.36 |
| 52-Week Price Change | -86.74% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 8.36 |
| Relative Strength Index (RSI) | 39.33 |
| Average Volume (20 Days) | 468.23K |
Income Statement
In the last 12 months, IGM Biosciences had revenue of 2.68M and earned -195.79M in profits. Earnings per share was -3.24.
| Revenue | 2.68M |
| Gross Profit | 2.68M |
| Operating Income | -208.58M |
| Net Income | -195.79M |
| EBITDA | -208.58M |
| EBIT | -208.58M |
| Earnings Per Share (EPS) | -3.24 |
Balance Sheet
The company has 26.5M in cash and 45.19M in debt, giving a net cash position of -18.69M.
| Cash & Cash Equivalents | 26.5M |
| Total Debt | 45.19M |
| Net Cash | -18.69M |
| Retained Earnings | -1.02B |
| Total Assets | 265.71M |
| Working Capital | 155.98M |
Cash Flow
In the last 12 months, operating cash flow was -153M and capital expenditures -5.85M, giving a free cash flow of -158.85M.
| Operating Cash Flow | -153M |
| Capital Expenditures | -5.85M |
| Free Cash Flow | -158.85M |
| FCF Per Share | -2.62 |
Margins
Gross margin is 100%, with operating and profit margins of -7.79K% and -7.31K%.
| Gross Margin | 100% |
| Operating Margin | -7.79K% |
| Pretax Margin | -7.31K% |
| Profit Margin | -7.31K% |
| EBITDA Margin | -7.79K% |
| EBIT Margin | -7.79K% |
| FCF Margin | -5.93K% |
Dividends & Yields
IGMS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -253.12% |
| FCF Yield | -207.61% |
Analyst Forecast
The average price target for IGMS is $2, which is 56.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 56.2% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -7.03 |
| Piotroski F-Score | 3 |